8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 22, 2026·SEC
Material company update
Feb 19, 2026·SEC
Amgen Inc.(AMGN)Earnings, Financials & Key Ratios
AMGN•NASDAQ
23.7× P/E·Price updated Jun 19, 2026
AboutAmgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.Show more
- Revenue$36.74B+9.9%
- EBITDA$15.84B+23.3%
- Net Income$7.71B+88.5%
- EPS (Diluted)14.23+88.2%
- Gross Margin70.8%+15.1%
- EBITDA Margin43.12%+12.2%
- Operating Margin29.06%+33.8%
- Net Margin20.99%+71.5%
- ROE106.1%+57.1%
AMGN Key Insights
Amgen Inc. (AMGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 103.1%
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 22.0% free cash flow margin
- ✓15 consecutive years of dividend growth
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy dividend yield of 2.8%
✗Weaknesses
- ✗High debt to equity ratio of 6.3x
- ✗Expensive at 21.1x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AMGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AMGN Price & Volume
Amgen Inc. (AMGN) stock price & volume — 10-year historical chart
Loading chart...
AMGN Growth Metrics
Amgen Inc. (AMGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years5.43%
5 Years7.64%
3 Years11.76%
TTM9.12%
Profit CAGR
10 Years1.06%
5 Years1.2%
3 Years5.58%
TTM31.47%
EPS CAGR
10 Years4.62%
5 Years2.94%
3 Years5.52%
TTM31.11%
Return on Capital
10 Years15.7%
5 Years14.56%
3 Years12.71%
Last Year15.95%
AMGN Recent Earnings
Amgen Inc. (AMGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$5.15+8.0%
$4.77
Rev
$8.6B+0.5%
$8.6B
Q1 2026
Feb 3, 2026Metric
Actual
Est
EPS
$5.29+11.8%
$4.73
Rev
$9.9B+4.1%
$9.5B
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$5.64+12.4%
$5.02
Rev
$9.6B+6.6%
$9.0B
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$6.02+14.0%
$5.28
Rev
$9.2B+2.6%
$8.9B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $5.15vs $4.77+8.0% | $8.6Bvs $8.6B+0.5% |
| Q1 2026 | Feb 3, 2026 | $5.29vs $4.73+11.8% | $9.9Bvs $9.5B+4.1% |
| Q4 2025 | Nov 4, 2025 | $5.64vs $5.02+12.4% | $9.6Bvs $9.0B+6.6% |
| Q3 2025 | Aug 5, 2025 | $6.02vs $5.28+14.0% | $9.2Bvs $8.9B+2.6% |
Based on last 12 quarters of dataView full earnings history →
AMGN Peer Comparison
Amgen Inc. (AMGN) competitors in Specialty and biologics-focused pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 GILD | 153.66B | 123.76 | 18.25 | 2.39% | 30.99% | 42.33% | 1.09 | |
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 VRTX | 114.88B | 451.63 | 29.48 | 9.57% | 35.4% | 23.93% | 0.21 | |
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 | |
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 |
Compare AMGN vs Peers
Amgen Inc. (AMGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AMGN Income Statement
Amgen Inc. (AMGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 22.85B | 23.75B | 23.36B | 25.42B | 25.98B | 26.32B | 28.19B | 33.42B | 36.74B | 37.24B |
Revenue Growth % | -0.62% | 3.93% | -1.62% | 8.83% | 2.18% | 1.32% | 7.09% | 18.57% | 9.92% | 9.12% |
Cost of Goods Sold | 4.07B | 4.1B | 4.36B | 6.16B | 6.45B | 6.41B | 8.41B | 12.86B | 10.73B | 10.63B |
COGS % of Revenue | 17.81% | 17.27% | 18.65% | 24.23% | 24.84% | 24.34% | 29.85% | 38.47% | 29.2% | - |
Gross Profit | 18.78B▲ 0% | 19.65B▲ 4.6% | 19.01B▼ 3.3% | 19.27B▲ 1.4% | 19.52B▲ 1.3% | 19.92B▲ 2.0% | 19.77B▼ 0.7% | 20.57B▲ 4.0% | 26.01B▲ 26.5% | 26.61B▲ 0% |
Gross Margin % | 82.19% | 82.73% | 81.35% | 75.77% | 75.16% | 75.66% | 70.15% | 61.53% | 70.8% | 71.46% |
Gross Profit Growth % | -0.26% | 4.61% | -3.26% | 1.36% | 1.35% | 2.01% | -0.71% | 4% | 26.48% | - |
Operating Expenses | 8.81B | 9.38B | 9.33B | 10.13B | 11.89B | 10.35B | 11.84B | 13.31B | 15.34B | 14.83B |
OpEx % of Revenue | 38.54% | 39.51% | 39.95% | 39.83% | 45.75% | 39.32% | 42.01% | 39.82% | 41.74% | - |
Selling, General & Admin | 4.87B | 5.33B | 5.15B | 5.73B | 5.37B | 5.41B | 6.18B | 7.1B | 7.05B | 6.95B |
SG&A % of Revenue | 21.31% | 22.45% | 22.04% | 22.54% | 20.66% | 20.57% | 21.92% | 21.23% | 19.19% | - |
Research & Development | 3.56B | 3.74B | 4.12B | 4.21B | 6.32B | 4.43B | 4.78B | 5.96B | 6.97B | 7.51B |
R&D % of Revenue | 15.59% | 15.74% | 17.62% | 16.55% | 24.34% | 16.84% | 16.97% | 17.84% | 18.98% | - |
Other Operating Expenses | 375M | 314M | 66M | 189M | 194M | 503M | 879M | 248M | 1.31B | 2M |
Operating Income | 9.97B▲ 0% | 10.26B▲ 2.9% | 9.67B▼ 5.7% | 9.14B▼ 5.5% | 7.64B▼ 16.4% | 9.57B▲ 25.2% | 7.9B▼ 17.4% | 7.26B▼ 8.1% | 10.68B▲ 47.1% | 11.78B▲ 0% |
Operating Margin % | 43.65% | 43.22% | 41.41% | 35.95% | 29.4% | 36.34% | 28.01% | 21.71% | 29.06% | 31.63% |
Operating Income Growth % | 1.83% | 2.91% | -5.74% | -5.53% | -16.41% | 25.23% | -17.45% | -8.09% | 47.09% | - |
EBITDA | 11.93B | 12.21B | 11.88B | 12.74B | 11.04B | 12.98B | 11.97B | 12.85B | 15.84B | 15.63B |
EBITDA Margin % | 52.2% | 51.41% | 50.85% | 50.11% | 42.48% | 49.32% | 42.45% | 38.45% | 43.12% | 41.98% |
EBITDA Growth % | 0.24% | 2.36% | -2.69% | 7.24% | -13.37% | 17.63% | -7.82% | 7.37% | 23.29% | 20.02% |
D&A (Non-Cash Add-back) | 1.96B | 1.95B | 2.21B | 3.6B | 3.4B | 3.42B | 4.07B | 5.59B | 5.17B | 3.78B |
EBIT | 10.9B | 10.94B | 10.43B | 9.39B | 7.9B | 8.75B | 10.73B | 7.76B | 10.68B | 13.56B |
Net Interest Income | -376M | -718M | -702M | -1.26B | -1.2B | -1.41B | -2.88B | -3.15B | -2.75B | -2.7B |
Interest Income | 928M | 674M | 587M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 1.3B | 1.39B | 1.29B | 1.26B | 1.2B | 1.41B | 2.88B | 3.15B | 2.75B | 2.7B |
Other Income/Expense | -376M | -718M | -536M | -1.01B | -938M | -2.22B | -42M | -2.65B | -1.7B | -2.69B |
Pretax Income | 9.6B▲ 0% | 9.54B▼ 0.5% | 9.14B▼ 4.3% | 8.13B▼ 11.0% | 6.7B▼ 17.6% | 7.35B▲ 9.6% | 7.86B▲ 6.9% | 4.61B▼ 41.3% | 8.98B▲ 94.7% | 9.09B▲ 0% |
Pretax Margin % | 42% | 40.19% | 39.11% | 31.99% | 25.79% | 27.91% | 27.86% | 13.79% | 24.43% | 24.4% |
Income Tax | 7.62B | 1.15B | 1.3B | 869M | 808M | 794M | 1.14B | 519M | 1.26B | 1.29B |
Effective Tax Rate % | 79.38% | 12.06% | 14.18% | 10.68% | 12.06% | 10.81% | 14.49% | 11.26% | 14.09% | 14.16% |
Net Income | 1.98B▲ 0% | 8.39B▲ 324.2% | 7.84B▼ 6.6% | 7.26B▼ 7.4% | 5.89B▼ 18.9% | 6.55B▲ 11.2% | 6.72B▲ 2.5% | 4.09B▼ 39.1% | 7.71B▲ 88.5% | 7.8B▲ 0% |
Net Margin % | 8.66% | 35.35% | 33.57% | 28.57% | 22.68% | 24.89% | 23.83% | 12.24% | 20.99% | 20.95% |
Net Income Growth % | -74.37% | 324.15% | -6.58% | -7.37% | -18.87% | 11.18% | 2.52% | -39.11% | 88.53% | 31.47% |
Net Income (Continuing) | 1.98B | 8.39B | 7.84B | 7.26B | 5.89B | 6.55B | 6.72B | 4.09B | 7.71B | 7.8B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 2.69▲ 0% | 12.62▲ 369.1% | 12.88▲ 2.1% | 12.31▼ 4.4% | 10.28▼ 16.5% | 12.11▲ 17.8% | 12.49▲ 3.1% | 7.56▼ 39.5% | 14.23▲ 88.2% | 14.34▲ 0% |
EPS Growth % | -73.73% | 369.15% | 2.06% | -4.43% | -16.49% | 17.8% | 3.14% | -39.47% | 88.23% | 31.11% |
EPS (Basic) | 2.71 | 12.70 | 12.96 | 12.40 | 10.34 | 12.18 | 12.56 | 7.62 | 14.33 | - |
Diluted Shares Outstanding | 735M | 665M | 609M | 590M | 573M | 541M | 538M | 541M | 542M | 544M |
Basic Shares Outstanding | 731M | 661M | 605M | 586M | 570M | 538M | 535M | 541M | 538M | 540M |
Dividend Payout Ratio | 170.04% | 41.78% | 44.75% | 51.69% | 68.1% | 64.04% | 67.83% | 118.14% | 66.45% | - |
AMGN Balance Sheet
Amgen Inc. (AMGN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 49.48B | 37.62B | 18.44B | 21.14B | 19.39B | 22.19B | 30.33B | 29.03B | 29.06B | 31.48B |
Cash & Short-Term Investments | 41.68B | 29.3B | 8.91B | 10.65B | 8.04B | 9.3B | 10.94B | 11.97B | 9.13B | 12.04B |
Cash Only | 3.8B | 6.95B | 6.04B | 6.27B | 7.99B | 7.63B | 10.94B | 11.97B | 9.13B | 12.04B |
Short-Term Investments | 37.88B | 22.36B | 2.87B | 4.38B | 48M | 1.68B | 0 | 0 | 0 | 0 |
Accounts Receivable | 3.24B | 3.58B | 4.06B | 4.53B | 5.84B | 6.39B | 7.94B | 7.5B | 9.57B | 9.14B |
Days Sales Outstanding | 51.71 | 55.03 | 63.39 | 64.96 | 82.04 | 88.63 | 102.83 | 81.91 | 95.07 | 87.97 |
Inventory | 2.83B | 2.94B | 3.58B | 3.89B | 4.09B | 4.93B | 9.52B | 7B | 6.22B | 6.19B |
Days Inventory Outstanding | 254.22 | 261.67 | 300.31 | 230.71 | 231.08 | 280.9 | 412.84 | 198.65 | 211.77 | 217.58 |
Other Current Assets | 1.73B | 1.79B | 1.89B | 2.08B | 200M | 355M | 281M | 419M | 4.13B | 4.11B |
Total Non-Current Assets | 30.48B | 28.8B | 41.27B | 41.8B | 41.78B | 42.94B | 66.82B | 62.81B | 61.53B | 61.03B |
Property, Plant & Equipment | 4.99B | 4.96B | 4.93B | 4.89B | 5.18B | 5.43B | 5.94B | 6.54B | 7.91B | 8.22B |
Fixed Asset Turnover | 4.58x | 4.79x | 4.74x | 5.20x | 5.01x | 4.85x | 4.74x | 5.11x | 4.64x | 4.93x |
Goodwill | 14.76B | 14.7B | 14.7B | 14.69B | 14.89B | 15.53B | 18.63B | 18.64B | 18.68B | 18.67B |
Intangible Assets | 8.61B | 7.44B | 19.41B | 16.59B | 15.18B | 16.08B | 32.64B | 27.7B | 22.28B | 21.38B |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 4.71B | 5.36B | 0 | 12.45B |
Other Non-Current Assets | 2.12B | 1.7B | 2.22B | 5.64B | 6.52B | 5.9B | 4.9B | 4.58B | 12.66B | 12.76B |
Total Assets | 79.95B▲ 0% | 66.42B▼ 16.9% | 59.71B▼ 10.1% | 62.95B▲ 5.4% | 61.16B▼ 2.8% | 65.12B▲ 6.5% | 97.15B▲ 49.2% | 91.84B▼ 5.5% | 90.59B▼ 1.4% | 92.5B▲ 0% |
Asset Turnover | 0.29x | 0.36x | 0.39x | 0.40x | 0.42x | 0.40x | 0.29x | 0.36x | 0.41x | 0.41x |
Asset Growth % | 3% | -16.93% | -10.1% | 5.43% | -2.83% | 6.47% | 49.19% | -5.47% | -1.36% | -1.98% |
Total Current Liabilities | 9.02B | 13.49B | 12.84B | 11.65B | 12.18B | 15.69B | 18.39B | 23.1B | 25.49B | 24.95B |
Accounts Payable | 1.35B | 1.21B | 1.37B | 1.42B | 1.37B | 1.57B | 1.59B | 1.91B | 20.89B | 0 |
Days Payables Outstanding | 121.28 | 107.43 | 114.88 | 84.21 | 77.25 | 89.57 | 68.97 | 54.16 | 710.68 | 229.59 |
Short-Term Debt | 1.15B | 4.42B | 2.95B | 91M | 87M | 1.59B | 1.44B | 3.55B | 4.6B | 5.44B |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.27B | 1.54B | 1.54B | 1.57B | 1.62B | 1.1B | 1.38B | 1.33B | 0 | 19.52B |
Current Ratio | 5.49x | 2.79x | 1.44x | 1.81x | 1.59x | 1.41x | 1.65x | 1.26x | 1.14x | 1.26x |
Quick Ratio | 5.17x | 2.57x | 1.16x | 1.48x | 1.26x | 1.10x | 1.13x | 0.95x | 0.90x | 1.01x |
Cash Conversion Cycle | 184.65 | 209.27 | 248.82 | 211.46 | 235.86 | 279.96 | 446.71 | 226.4 | -403.83 | 75.96 |
Total Non-Current Liabilities | 45.69B | 40.43B | 37.2B | 41.89B | 42.28B | 45.77B | 72.53B | 62.86B | 56.44B | 58.36B |
Long-Term Debt | 34.19B | 29.51B | 26.95B | 32.9B | 33.22B | 37.35B | 63.17B | 56.55B | 50.01B | 51.89B |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 1.17B | 864M | 606M | 0 | 0 | 11M | 2.35B | 1.62B | 1.37B | 5.55B |
Other Non-Current Liabilities | 10.34B | 10.05B | 9.64B | 8.99B | 9.06B | 8.41B | 7.01B | 4.7B | 5.07B | 5.13B |
Total Liabilities | 54.71B | 53.92B | 50.03B | 53.54B | 54.47B | 61.46B | 90.92B | 85.96B | 81.93B | 83.31B |
Total Debt | 35.34B | 33.93B | 29.9B | 32.99B | 33.31B | 38.95B | 64.61B | 60.1B | 54.6B | 57.32B |
Net Debt | 31.54B | 26.98B | 23.87B | 26.72B | 25.32B | 31.32B | 53.67B | 48.13B | 45.48B | 45.28B |
Debt / Equity | 1.40x | 2.71x | 3.09x | 3.51x | 4.97x | 10.64x | 10.37x | 10.23x | 6.31x | 6.24x |
Debt / EBITDA | 2.96x | 2.78x | 2.52x | 2.59x | 3.02x | 3.00x | 5.40x | 4.68x | 3.45x | 3.67x |
Net Debt / EBITDA | 2.64x | 2.21x | 2.01x | 2.10x | 2.29x | 2.41x | 4.48x | 3.75x | 2.87x | 2.90x |
Interest Coverage | 8.36x | 7.86x | 8.09x | 7.44x | 6.60x | 6.22x | 3.73x | 2.46x | 3.88x | 5.02x |
Total Equity | 25.24B▲ 0% | 12.5B▼ 50.5% | 9.67B▼ 22.6% | 9.41B▼ 2.7% | 6.7B▼ 28.8% | 3.66B▼ 45.4% | 6.23B▲ 70.2% | 5.88B▼ 5.7% | 8.66B▲ 47.3% | 9.19B▲ 0% |
Equity Growth % | -15.51% | -50.48% | -22.62% | -2.73% | -28.79% | -45.36% | 70.23% | -5.7% | 47.32% | 148.54% |
Book Value per Share | 34.34 | 18.80 | 15.88 | 15.95 | 11.69 | 6.77 | 11.58 | 10.86 | 15.97 | 16.89 |
Total Shareholders' Equity | 25.24B | 12.5B | 9.67B | 9.41B | 6.7B | 3.66B | 6.23B | 5.88B | 8.66B | 9.19B |
Common Stock | 30.99B | 31.25B | 31.53B | 31.8B | 32.1B | 32.51B | 33.07B | 33.53B | 8.66B | 0 |
Retained Earnings | -5.07B | -17.98B | -21.33B | -21.41B | -24.6B | -28.62B | -26.55B | -27.59B | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -679M | -769M | -528M | -985M | -796M | -231M | -289M | -66M | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AMGN Cash Flow Statement
Amgen Inc. (AMGN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 11.18B | 11.3B | 9.15B | 10.5B | 9.26B | 9.72B | 8.47B | 11.49B | 9.96B | 10.76B |
Operating CF Margin % | 48.92% | 47.57% | 39.17% | 41.29% | 35.65% | 36.93% | 30.05% | 34.38% | 27.1% | - |
Operating CF Growth % | 7.95% | 1.06% | -19% | 14.72% | -11.77% | 4.97% | -12.86% | 35.64% | -13.33% | 14.86% |
Net Income | 1.98B | 8.39B | 7.84B | 7.26B | 5.89B | 6.55B | 6.72B | 4.09B | 7.71B | 7.8B |
Depreciation & Amortization | 1.96B | 1.95B | 2.21B | 3.6B | 3.4B | 3.42B | 4.07B | 5.59B | 5.17B | 3.78B |
Stock-Based Compensation | 329M | 311M | 308M | 330M | 341M | 401M | 431M | 530M | 0 | 284M |
Deferred Taxes | -1.33B | -363M | -289M | -287M | -453M | -1.2B | -1.27B | -1.23B | -721M | -471M |
Other Non-Cash Items | 334M | 386M | -186M | -195M | 1.28B | 1.28B | -991M | 141M | -221M | 325M |
Working Capital Changes | 7.91B | 622M | -731M | -216M | -1.19B | -733M | -484M | 2.37B | -1.98B | -962M |
Change in Receivables | -58M | -378M | -504M | -427M | -429M | -746M | -1.01B | 441M | -2.68B | -1.37B |
Change in Inventory | 133M | -3M | -66M | -215M | -165M | -742M | 491M | 2.53B | 886M | 598M |
Change in Payables | 424M | -143M | 164M | 45M | -69M | 154M | -402M | 312M | 428M | -69M |
Cash from Investing | -4.02B | 14.34B | 5.71B | -5.4B | 733M | -6.04B | -26.2B | -1.05B | -1.94B | -2.21B |
Capital Expenditures | -664M | -738M | -618M | -608M | -880M | -936M | -1.11B | -1.1B | -1.86B | -2.16B |
CapEx % of Revenue | 2.91% | 3.11% | 2.65% | 2.39% | 3.39% | 3.56% | 3.94% | 3.28% | 5.06% | 5.8% |
Acquisitions | -19M | 195M | -13.62B | -3.22B | -2.69B | -3.73B | -26.99B | 0 | -53M | -53M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -148M | -145M | -52M | -75M | -35M | -12M | 225M | 50M | -32M | 0 |
Cash from Financing | -6.59B | -22.49B | -15.77B | -4.87B | -8.27B | -4.04B | 21.05B | -9.41B | -10.86B | -5.32B |
Debt Issued (Net) | 71M | -1.12B | -4.51B | 2.46B | 795M | 6.62B | 25.68B | -4.26B | -5.68B | -2.88B |
Equity Issued (Net) | -3.16B | -17.79B | -7.7B | -3.49B | -4.97B | -6.36B | 0 | -200M | 0 | 0 |
Dividends Paid | -3.37B | -3.51B | -3.51B | -3.75B | -4.01B | -4.2B | -4.56B | -4.83B | -5.12B | -3.85B |
Share Repurchases | -3.16B | -17.79B | -7.7B | -3.49B | -4.97B | -6.36B | 0 | -200M | 0 | 0 |
Other Financing | -140M | -68M | -42M | -90M | -78M | -103M | -72M | -124M | -52M | 1.41B |
Net Change in Cash | 559M▲ 0% | 3.15B▲ 462.6% | -908M▼ 128.9% | 229M▲ 125.2% | 1.72B▲ 652.4% | -360M▼ 120.9% | 3.31B▲ 1020.8% | 1.03B▼ 69.0% | -2.84B▼ 376.4% | 3.23B▲ 0% |
Free Cash Flow | 10.51B▲ 0% | 10.56B▲ 0.4% | 8.53B▼ 19.2% | 9.89B▲ 15.9% | 8.38B▼ 15.2% | 8.79B▲ 4.8% | 7.36B▼ 16.2% | 10.39B▲ 41.2% | 8.1B▼ 22.1% | 8.6B▲ 0% |
FCF Margin % | 46.01% | 44.46% | 36.52% | 38.9% | 32.26% | 33.37% | 26.11% | 31.1% | 22.05% | 23.09% |
FCF Growth % | 10.47% | 0.43% | -19.19% | 15.9% | -15.25% | 4.82% | -16.23% | 41.24% | -22.07% | -21.24% |
FCF per Share | 14.30 | 15.88 | 14.01 | 16.76 | 14.63 | 16.24 | 13.68 | 19.21 | 14.94 | 15.80 |
FCF Conversion (FCF/Net Income) | 5.65x | 1.35x | 1.17x | 1.45x | 1.57x | 1.48x | 1.26x | 2.81x | 1.29x | 1.10x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AMGN Key Ratios
Amgen Inc. (AMGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 7.18% | 44.48% | 70.73% | 76.13% | 73.16% | 126.47% | 135.79% | 67.55% | 106.1% | 89.41% |
Return on Invested Capital (ROIC) | 12.68% | 15.99% | 19.87% | 19.68% | 16.81% | 21.42% | 12.48% | 9.56% | 14.81% | 16.14% |
Gross Margin | 82.19% | 82.73% | 81.35% | 75.77% | 75.16% | 75.66% | 70.15% | 61.53% | 70.8% | 71.46% |
Net Margin | 8.66% | 35.35% | 33.57% | 28.57% | 22.68% | 24.89% | 23.83% | 12.24% | 20.99% | 20.95% |
Debt / Equity | 1.40x | 2.71x | 3.09x | 3.51x | 4.97x | 10.64x | 10.37x | 10.23x | 6.31x | 6.24x |
Interest Coverage | 8.36x | 7.86x | 8.09x | 7.44x | 6.60x | 6.22x | 3.73x | 2.46x | 3.88x | 5.02x |
FCF Conversion | 5.65x | 1.35x | 1.17x | 1.45x | 1.57x | 1.48x | 1.26x | 2.81x | 1.29x | 1.10x |
Revenue Growth | -0.62% | 3.93% | -1.62% | 8.83% | 2.18% | 1.32% | 7.09% | 18.57% | 9.92% | 9.12% |
Related:AMGN Dividend History·AMGN Revenue History·AMGN Price History·AMGN P/E History·AMGN Financial Ratios·AMGN Institutional Holders
AMGN SEC Filings & Documents
Amgen Inc. (AMGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
AMGN Frequently Asked Questions
Amgen Inc. (AMGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Amgen Inc. (AMGN) reported $37.24B in revenue for fiscal year 2025. This represents a 1594% increase from $2.20B in 1996.
Amgen Inc. (AMGN) grew revenue by 9.9% over the past year. This is steady growth.
Yes, Amgen Inc. (AMGN) is profitable, generating $7.80B in net income for fiscal year 2025 (21.0% net margin).
Dividend & Returns
Yes, Amgen Inc. (AMGN) pays a dividend with a yield of 2.80%. This makes it attractive for income-focused investors.
Amgen Inc. (AMGN) has a return on equity (ROE) of 106.1%. This is excellent, indicating efficient use of shareholder capital.
Amgen Inc. (AMGN) generated $8.60B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.